NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (World NEWSWIRE) — Journey Medical Company (“Journey Medical”), a spouse business of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) concentrated on determining, acquiring, producing and strategically commercializing innovative, differentiated dermatology products, these days announces the appointment of Ernest De Paolantonio as Main Financial Officer, powerful September 30, 2021.
Claude Maraoui, Journey Medical’s President and Main Govt Officer, said, “Ernie’s economic leadership, potent small business acumen and sizeable pharmaceutical experience make him an critical addition to our sturdy administration workforce as we continue on to expand our footprint in the dermatology space. We glimpse forward to our collaboration and mutual success.”
Mr. De Paolantonio has additional than 40 many years of money and company working experience in the pharmaceutical field. Most lately, he was Chief Monetary Officer of Teligent, Inc., a specialty generic pharmaceutical organization. Prior, he held many management positions through his profession like Main Fiscal Officer at Fortovia Therapeutics Inc., a privately held health care enterprise, Chief Economical Officer, Secretary and Treasurer at BioDelivery Sciences Intercontinental, Inc., a public specialty pharmaceutical organization and Main Monetary Officer of CorePharma LLC, a privately held specialty generic pharmaceutical firm. He also held finance and controller positions in roles of expanding responsibility at Colombia Laboratories. Mr. De Paolantonio commenced his job at GlaxoSmithKline, where he put in extra than 17 several years in economic roles, which include serving as a group controller accountable for $3.5 billion in gross sales. A licensed CPA, he been given his B.A. from Lycoming Higher education and his MBA in Finance from Saint Joseph’s College.
“Journey Medical’s impressive progress, robust management staff and commitment to commercializing innovative dermatologic solutions make this a very compelling option,” extra Mr. De Paolantonio. “I glimpse forward to encouraging the Organization execute its strategic program as we grow our product portfolio and continue to deliver significant money development.”
About Journey Health-related Corporation
Journey Healthcare Company (“Journey Medical”) is concentrated on determining, acquiring, building and strategically commercializing impressive, differentiated dermatology goods as a result of its efficient product sales and marketing design. The business now markets seven products and solutions that help treat and recover prevalent pores and skin problems. The Journey Professional medical workforce is comprised of business experts with intensive expertise commercializing some of the most successful prescription dermatology manufacturers. Journey Professional medical is positioned in Scottsdale, Arizona and is a companion organization of Fortress Biotech, Inc. (NASDAQ: FBIO). For supplemental data about Journey Medical, visit www.journeymedicalcorp.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an modern biopharmaceutical corporation that was ranked in Deloitte’s 2019 and 2020 Technologies Fast 500™, once-a-year rankings of the speediest-escalating North American firms in the technological know-how, media, telecommunications, lifetime sciences and energy tech sectors, centered on percentages of fiscal calendar year income development around a few-yr intervals. Fortress is targeted on getting, establishing and commercializing superior-possible promoted and growth-phase medication and drug candidates. The firm has seven marketed prescription pharmaceutical goods and about 25 applications in improvement at Fortress, at its majority-owned and the greater part-controlled partners and at associates it established and in which it retains important minority possession positions. Such merchandise candidates span six large-current market parts, which include oncology, scarce disorders and gene treatment, which enable it to build worth for shareholders. Fortress improvements its diversified pipeline by a streamlined working composition that fosters efficient drug growth. The Fortress model is pushed by a environment-class company progress crew that is focused on leveraging its major biopharmaceutical business abilities to further more extend the company’s portfolio of merchandise alternatives. Fortress has established partnerships with some of the world’s primary tutorial study establishments and biopharmaceutical companies to maximize each and every chance to its entire possible, such as Alexion Prescription drugs, Inc., AstraZeneca, Metropolis of Hope, Fred Hutchinson Cancer Research Heart, St. Jude Children’s Research Clinic, Nationwide Children’s Hospital and Sentynl Therapeutics, Inc. For more data, visit www.fortressbiotech.com.
Ahead-Searching Statements
This press launch may include “forward-seeking statements” inside of the that means of Portion 27A of the Securities Act of 1933 and Segment 21E of the Securities Trade Act of 1934, as amended. As utilized under and in the course of this push release, the phrases “we”, “us” and “our” could refer to Fortress individually or jointly with just one or more spouse companies, as dictated by context. This kind of statements involve, but are not constrained to, any statements relating to our growth method and solution improvement applications and any other statements that are not historical facts. Forward-on the lookout statements are primarily based on management’s present-day expectations and are issue to challenges and uncertainties that could negatively have an impact on our enterprise, running effects, fiscal affliction and stock value. Elements that could result in true effects to differ materially from those people now expected contain: threats relating to our growth technique our capability to attain, conduct beneath and keep funding and strategic agreements and associations dangers relating to the final results of exploration and growth routines uncertainties relating to preclinical and scientific testing hazards relating to the timing of starting up and completing clinical trials our dependence on third-get together suppliers dangers relating to the COVID-19 outbreak and its opportunity effects on our employees’ and consultants’ potential to comprehensive get the job done in a well timed manner and on our capability to receive more financing on favorable phrases or at all our skill to catch the attention of, integrate and keep important personnel the early phase of goods below progress our want for considerable extra cash federal government regulation patent and mental residence matters competitors as properly as other hazards explained in our SEC filings. We expressly disclaim any obligation or enterprise to release publicly any updates or revisions to any forward-seeking statements contained herein to reflect any adjust in our anticipations or any modifications in events, circumstances or conditions on which any these kinds of statement is centered, besides as could be demanded by legislation, and we assert the defense of the secure harbor for forward-looking statements contained in the Personal Securities Litigation Reform Act of 1995. The information and facts contained herein is supposed to be reviewed in its totality, and any stipulations, circumstances or provisos that apply to a provided piece of data in a person portion of this push launch should be examine as making use of mutatis mutandis to every other instance of this sort of details appearing herein.
Firm Contacts:
Jaclyn Jaffe and Bill Begien
Fortress Biotech, Inc.
(781) 652-4500
[email protected]
Media Relations Speak to:
Tony Plohoros
6 Levels
(908) 591-2839
[email protected]
